Eosinophilic Esophagitis Clinical Trial
Official title:
Monocentric Retrospective Observational Study for Validation of Meta-analysis of the Metatrascryptome and Transcriptome of Eosynophyl Esophagitis (EoE TaMMA)
This is a retrospective monocentric observational study involving patients with Eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), and controls (patients without EoE and GERD). To validate the EoE-related markers obtained with the EoE TaMMA web app (such as CCL26, TBX5, NOX4, FGF7, CXCL14, ADAMTS5, PDGFRA, CXCL12, ACVRL1, POSTN, and LTBP4), we will stain and analyze EoE, GERD, and controls Formalin-fixed paraffin-embedded (FFPE) tissue samples already stored in the pathological laboratory of OSR. For this reason, this project will be accomplished thanks to the collaboration with prof. Doglioni's team at OSR.
Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease, primarily activated by food antigens, with the concomitant accumulation of eosinophils within the esophageal mucosal layer where the Th2-response-specific interleukin (IL) 5 and IL13 play a key role during its pathogenesis. EoE positions as an uncommon disease, with a suggested genetic basis and a 3:1 male preponderance. Its incidence rate varies between 0.1 and 1.2 cases per 10,0009 and increases annually. EoE symptoms include difficulty with eating, failure to thrive, vomiting, chest and/or abdominal pain, dysphagia, and food impaction, histologically associated with esophageal linear furrows with loss of vascularity, mucosal rings, a small-caliber lumen, strictures, mucosal exudates, and, less commonly, polyps and ulcerations. The currently adopted therapies are mainly based on proton pump inhibition, topical administration of glucocorticoids, and changes in dietary habits. However, in most patients, eosinophilic esophagitis remains a chronic disease, and if treatment is stopped, inflammation ensues and symptoms recur. This may hamper the quality of life, including vitality and general health scores, and complications may develop. Therefore, the complete comprehension of the mechanisms occurring during EoE pathogenesis remains of paramount importance to implementing and improving the therapeutic lines of intervention, ameliorating the overall patients' wellness. A straightforward and facilitated EoE clinical diagnosis is still missing, since EoE provokes in patients symptoms overlapping with other disease manifestations, such as gastroesophageal reflux disease (GERD), eosinophilic gastrointestinal disease, and achalasia. Along with the mucosal immunity alterations, the epithelial barrier function impairment does remain a hallmark of EoE, in terms of both increased permeability and antigen sensing and EoE TaMMA . Indeed, at the mucosal level, EoE is featured by a striking pattern of dilated interepithelial spaces, with down-regulation of proteins associated with barrier function and adhesion molecules, in turn, modulated via an IL13-dependent mechanism. As a consequence, altered epithelial permeability can lead to a permissive environment that enhances antigen presentation, which in turn leads to persistent chronic inflammation. Despite some anatomical and molecular characterizations employed as a kind of gold standard for the definition of the EoE pathogenesis, a meta-analysis of the molecular studies may improve the understanding of the physiopathology of the disease and define molecular markers helpful for a straightforward diagnosis of EoE has not been performed yet. We recently developed and released the Inflammatory Bowel Disease (IBD) Transcriptome and Metatranscriptome Meta-Analysis web app (IBD TaMMA, https://ibd-meta-analysis.herokuapp.com/), a complete survey of all public data sets generated for IBD-related studies. TaMMA has contributed to the field of omics data meta-analysis by providing an open source framework that will enable the community to easily access, query, and 'play' with the data through a user-friendly web application and offering an unprecedented opportunity to define new hypotheses and insights for better understanding the pathogenesis of IBD. Considering the utility that IBD TaMMA has been increasingly showing over the last months, we developed a similar meta-analysis of EoE-related public data sets visualized in an interactive web app, the EoE TaMMA, that includes studies analyzing EoE, GERD and controls (without EoE and GERD). EoE-related phenotypes were confirmed throughout the web app. To further consolidate the platform, we are proposing the validation of EoE TaMMA results in an independent cohort of EoE and GERD patients, by taking advantage of the EoE and GERD. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03382678 -
CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry
|
||
Completed |
NCT05083312 -
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
|
Phase 3 | |
Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
Completed |
NCT03633617 -
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
|
Phase 3 | |
Completed |
NCT04941742 -
The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Validation Phase)
|
||
Terminated |
NCT04543409 -
A Study of Benralizumab in Patients With Eosinophilic Esophagitis
|
Phase 3 | |
Terminated |
NCT02314455 -
Esophageal Absorption in EoE
|
N/A | |
Completed |
NCT01953575 -
Mucosal Impedance and Eosinophilic Esophagitis
|
N/A | |
Completed |
NCT01386112 -
Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04991935 -
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
|
Phase 3 | |
Not yet recruiting |
NCT05896891 -
San Raffaele EoE Biobank
|
||
Active, not recruiting |
NCT05482256 -
A Study of Detergents in the Pathogenesis of Eosinophilic Esophagitis
|
N/A | |
Recruiting |
NCT05485155 -
Zemaira Eosinophilic Esophagitis Pilot Study
|
Phase 2 | |
Recruiting |
NCT04149470 -
Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
|
Phase 4 | |
Recruiting |
NCT04416217 -
Eosinophilic Esophagitis Steroid Safety Study
|
||
Completed |
NCT05084963 -
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
|
Phase 2 | |
Completed |
NCT02579876 -
Milk Patch for Eosinophilic Esophagitis
|
Phase 2 | |
Recruiting |
NCT02331849 -
Esophageal Motility in Eosinophilic Esophagitis Evaluated by High Resolution Manometry.
|
N/A | |
Active, not recruiting |
NCT02202590 -
Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus
|
N/A | |
Active, not recruiting |
NCT05176249 -
Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population
|